Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Pharmacology Study of Oral Edaravone via PEG in ALS Patients
jRCT2080225036Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of edaravone in amyotrophic lateral sclerosis (ALS), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Pharmacokinetics of unchanged edaravone after oral administration via PEG. Started Jan 2020; status: completed.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT2080225036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225036.